Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.

Qadri F, Akhtar M, Bhuiyan TR, Chowdhury MI, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Lundgren A, Wiklund G, Kaim J, Löfstrand M, Carlin N, Bourgeois AL, Maier N, Fix A, Wierzba T, Walker RI, Svennerholm AM.

Lancet Infect Dis. 2019 Nov 19. pii: S1473-3099(19)30571-7. doi: 10.1016/S1473-3099(19)30571-7. [Epub ahead of print]

2.

Preface.

Walker RI, Riddle MS, Clifford A.

Vaccine. 2019 Aug 7;37(34):4767. doi: 10.1016/j.vaccine.2019.06.085. Epub 2019 Jul 9. No abstract available.

3.

A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children.

Raqib R, Sarker P, Zaman K, Alam NH, Wierzba TF, Maier N, Talukder K, Baqui AH, Suvarnapunya AE, Qadri F, Walker RI, Fix A, Venkatesan MM.

Hum Vaccin Immunother. 2019;15(6):1326-1337. doi: 10.1080/21645515.2019.1575165. Epub 2019 Mar 19.

PMID:
30794051
4.

Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.

Akhtar M, Chowdhury MI, Bhuiyan TR, Kaim J, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Begum YA, Sharif MZ, Islam LN, Carlin N, Maier N, Fix A, Wierzba TF, Walker RI, Bourgeois AL, Svennerholm AM, Qadri F, Lundgren A.

Vaccine. 2019 Sep 3;37(37):5645-5656. doi: 10.1016/j.vaccine.2018.11.040. Epub 2018 Nov 22.

5.

Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference.

Walker RI, Wierzba TF, Mani S, Bourgeois AL.

Vaccine. 2017 Dec 14;35(49 Pt A):6775-6782. doi: 10.1016/j.vaccine.2017.09.045. Epub 2017 Oct 4.

6.

Individual-specific changes in the human gut microbiota after challenge with enterotoxigenic Escherichia coli and subsequent ciprofloxacin treatment.

Pop M, Paulson JN, Chakraborty S, Astrovskaya I, Lindsay BR, Li S, Bravo HC, Harro C, Parkhill J, Walker AW, Walker RI, Sack DA, Stine OC.

BMC Genomics. 2016 Jun 8;17:440. doi: 10.1186/s12864-016-2777-0.

7.

Status of vaccine research and development for norovirus.

Riddle MS, Walker RI.

Vaccine. 2016 Jun 3;34(26):2895-2899. doi: 10.1016/j.vaccine.2016.03.077. Epub 2016 Mar 29. Review.

8.

Status of vaccine research and development for enterotoxigenic Escherichia coli.

Bourgeois AL, Wierzba TF, Walker RI.

Vaccine. 2016 Jun 3;34(26):2880-2886. doi: 10.1016/j.vaccine.2016.02.076. Epub 2016 Mar 15.

9.

Status of vaccine research and development for Shigella.

Mani S, Wierzba T, Walker RI.

Vaccine. 2016 Jun 3;34(26):2887-2894. doi: 10.1016/j.vaccine.2016.02.075. Epub 2016 Mar 12. Review.

10.

Recommendations regarding the development of combined enterotoxigenic Eschericha coli and Shigella vaccines for infants.

Walker RI, Clifford A.

Vaccine. 2015 Feb 18;33(8):946-53. doi: 10.1016/j.vaccine.2014.11.048. Epub 2014 Dec 8.

PMID:
25500172
11.

An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children.

Walker RI.

Vaccine. 2015 Feb 18;33(8):954-65. doi: 10.1016/j.vaccine.2014.11.049. Epub 2014 Dec 5. Review.

PMID:
25482842
12.

Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.

Clin Vaccine Immunol. 2014 Mar;21(3):366-82. doi: 10.1128/CVI.00683-13. Epub 2014 Jan 8.

13.

Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.

Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL.

Infect Immun. 2013 Dec;81(12):4470-7. doi: 10.1128/IAI.00859-13. Epub 2013 Sep 23.

14.

Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA.

Clin Vaccine Immunol. 2011 Oct;18(10):1719-27. doi: 10.1128/CVI.05194-11. Epub 2011 Aug 18.

15.

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D, Walker RI, Clements JD, Walz S, Gibbs P, Burg EF 3rd, Moran AP, Applebee L, Bourgeois AL.

Infect Immun. 2010 Apr;78(4):1750-9. doi: 10.1128/IAI.01021-09. Epub 2010 Jan 19.

16.

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.

Gaston JS, Inman RD, Ryan ET, Venkatesan MM, Barry EM, Hale TL, Bourgeois AL, Walker RI.

Vaccine. 2009 Sep 4;27(40):5432-4. doi: 10.1016/j.vaccine.2009.06.107. Epub 2009 Jul 28.

PMID:
19643213
17.

Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease.

Walker RI, Steele D, Aguado T; Ad Hoc ETEC Technical Expert Committee.

Vaccine. 2007 Mar 30;25(14):2545-66. Epub 2006 Dec 19. Review.

PMID:
17224212
18.

Vaccine potential for inactivated shigellae.

Osorio M, Bray MD, Walker RI.

Vaccine. 2007 Feb 19;25(9):1581-92. Epub 2006 Nov 20.

PMID:
17178431
19.

New vaccines against enteric bacteria for children in less developed countries.

Walker RI.

Expert Rev Vaccines. 2005 Dec;4(6):807-12. Review.

PMID:
16372876
20.

Enteric vaccines for pediatric use. Workshop summary.

Walker RI, Van De Verg LL, Hall RH, Schmitt CK, Woo K, Hale V.

Vaccine. 2005 Nov 16;23(46-47):5432-9. Epub 2005 Apr 2.

PMID:
16286159
21.

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3735-45. Epub 2005 Jul 21.

PMID:
16095766
22.

Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine.

Burr DH, Rollins D, Lee LH, Pattarini DL, Walz SS, Tian JH, Pace JL, Bourgeois AL, Walker RI.

Vaccine. 2005 Jul 29;23(34):4315-21.

PMID:
16005742
23.

Campylobacter vaccine development:a key to controlling enteric diseases.

Walker RI.

Expert Opin Investig Drugs. 1999 Feb;8(2):107-13.

PMID:
15992066
24.

Case report: pulmonary blastoma: presentation of two atypical cases and review of the literature.

Walker RI, Suvarna K, Matthews S.

Br J Radiol. 2005 May;78(929):437-40. Review.

PMID:
15845939
26.

Meeting summary: possibilities for active and passive vaccination against opportunistic infections.

Walker RI, Blanchard T, Braun JM, Cebra JJ, Cross AS, Fattom A, Giannasca PJ, Holder IA, Huebner J, Matthews R, Pier GB, Romani L, von Specht BU, Trautmann M.

Vaccine. 2004 Feb 17;22(7):801-4. No abstract available.

PMID:
15040930
27.

In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection.

Prendergast MM, Tribble DR, Baqar S, Scott DA, Ferris JA, Walker RI, Moran AP.

Infect Immun. 2004 Feb;72(2):916-22.

29.

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.

Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI.

Infect Immun. 2001 Jun;69(6):3581-90.

30.

Inactivated whole-cell bacterial vaccines: current status and novel strategies.

Pace JL, Rossi HA, Esposito VM, Frey SM, Tucker KD, Walker RI.

Vaccine. 1998 Oct;16(16):1563-74. Review.

PMID:
9711805
31.

Automated fluorescent analysis procedure for enzymatic mutation detection.

Del Tito BJ Jr, Poff HE 3rd, Novotny MA, Cartledge DM, Walker RI 2nd, Earl CD, Bailey AL.

Clin Chem. 1998 Apr;44(4):731-9.

32.

Problems and priorities for controlling opportunistic pathogens with new antimicrobial strategies; an overview of current literature.

Araneo BA, Cebra JJ, Beuth J, Fuller R, Heidt PJ, Midvedt T, Nord CE, Nieuwenhuis P, Manson WL, Pulverer G, Rusch VC, Tanaka R, van der Waaij D, Walker RI, Wells CL.

Zentralbl Bakteriol. 1996 Apr;283(4):431-65. Review.

PMID:
8737943
33.

Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates.

Baqar S, Bourgeois AL, Schultheiss PJ, Walker RI, Rollins DM, Haberberger RL, Pavlovskis OR.

Vaccine. 1995 Jan;13(1):22-8.

PMID:
7539199
34.
35.

Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant.

Rollwagen FM, Pacheco ND, Clements JD, Pavlovskis O, Rollins DM, Walker RI.

Vaccine. 1993 Oct;11(13):1316-20.

PMID:
8296484
36.

Therapies for radiation injuries: research perspectives.

Brook I, Ledney GD, Madonna GS, DeBell RM, Walker RI.

Mil Med. 1992 Mar;157(3):130-6. Review.

PMID:
1603404
37.

Immunomodulators: a key to controlling infections in military personnel?

Madonna GS, Ledney GD, Walker RI.

Mil Med. 1991 Oct;156(10):578-9. No abstract available.

PMID:
1749508
38.

Significance of flagella in colonization resistance of rabbits immunized with Campylobacter spp.

Pavlovskis OR, Rollins DM, Haberberger RL Jr, Green AE, Habash L, Strocko S, Walker RI.

Infect Immun. 1991 Jul;59(7):2259-64.

39.

Protection against ovine footrot using a topical preparation of zinc sulphate.

Marshall DJ, Walker RI, Coveny RE.

Aust Vet J. 1991 May;68(5):186-8. No abstract available.

PMID:
1883300
40.

The effect of footrot on body weight and wool growth of sheep.

Marshall DJ, Walker RI, Cullis BR, Luff MF.

Aust Vet J. 1991 Feb;68(2):45-9.

PMID:
2025200
41.

Serum antibody responses in sheep after natural infection with Bacteroides nodosus.

Whittington RJ, Marshall DJ, Walker RI, Turner MJ.

Aust Vet J. 1990 Mar;67(3):98-101.

PMID:
2375715
42.

Intestinal barriers to bacteria and their toxins.

Walker RI, Owen RL.

Annu Rev Med. 1990;41:393-400. Review.

PMID:
2184739
43.

Trehalose dimycolate enhances resistance to infection in neutropenic animals.

Madonna GS, Ledney GD, Elliott TB, Brook I, Ulrich JT, Myers KR, Patchen ML, Walker RI.

Infect Immun. 1989 Aug;57(8):2495-501.

44.

Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock.

Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, MacVittie TJ, Walker RI, Parrillo JE.

J Clin Invest. 1989 Jan;83(1):243-51. Erratum in: J Clin Invest 1989 Mar;83(3):1087.

45.

Selective association and transport of Campylobacter jejuni through M cells of rabbit Peyer's patches.

Walker RI, Schmauder-Chock EA, Parker JL, Burr D.

Can J Microbiol. 1988 Oct;34(10):1142-7.

PMID:
3196964
46.

Prospects for management of gastrointestinal injury associated with the acute radiation syndrome.

Dubois A, Walker RI.

Gastroenterology. 1988 Aug;95(2):500-7. Review.

PMID:
3292340
47.

Aeromonas and Plesiomonas in the environment: value of differential biotyping of aeromonads.

Joseph SW, Carnahan A, Rollins D, Walker RI.

J Diarrhoeal Dis Res. 1988 Jun;6(2):80-7. Review. No abstract available.

PMID:
3077630
48.

Effect of antimicrobial therapy on bowel flora and bacterial infection in irradiated mice.

Brook I, Walker RI, MacVittie TJ.

Int J Radiat Biol Relat Stud Phys Chem Med. 1988 May;53(5):709-16.

PMID:
3283066
49.

Cardiovascular performance with E. coli challenges in a canine model of human sepsis.

Natanson C, Danner RL, Fink MP, MacVittie TJ, Walker RI, Conklin JJ, Parrillo JE.

Am J Physiol. 1988 Mar;254(3 Pt 2):H558-69.

PMID:
3279822
50.

Mucosal and systemic immunity to Campylobacter jejuni in rabbits after gastric inoculation.

Burr DH, Caldwell MB, Bourgeois AL, Morgan HR, Wistar R Jr, Walker RI.

Infect Immun. 1988 Jan;56(1):99-105.

Supplemental Content

Loading ...
Support Center